# Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer

> **NCT02947386** · PHASE1 · COMPLETED · sponsor: **Roswell Park Cancer Institute** · enrollment: 7 (actual)

## Conditions studied

- EGFR Gene Mutation
- Recurrent Non-Small Cell Lung Carcinoma
- Stage IIIA Non-Small Cell Lung Cancer
- Stage IIIB Non-Small Cell Lung Cancer
- Stage IV Non-Small Cell Lung Cancer

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Nimotuzumab
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT02947386
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-29
- **Primary completion:** 2021-04-15
- **Final completion:** 2022-09-08
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2023-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02947386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02947386, "Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02947386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*